| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
Smyrindioloside does not have a well-defined biological target. As a coumarin-type natural product, it may interact with various enzymes or receptors. Coumarins are known to exhibit a wide range of biological activities, including anti-inflammatory, antioxidant, and antimicrobial properties. However, specific targets for Smyrindioloside have not been extensively characterized.
|
|---|---|
| ln Vitro |
In vitro studies of Smyrindioloside are limited. As a natural product, it is used in biochemical experiments and drug synthesis research. Its biological activities, if any, have not been extensively characterized in the available literature. The compound is primarily used as a research tool for studying natural products and their chemical properties.
|
| ln Vivo |
In vivo activity of Smyrindioloside has not been characterized in the available literature. The compound is primarily used as a research tool for biochemical experiments and drug synthesis research. Detailed in vivo efficacy data are not reported.
|
| Enzyme Assay |
In vitro assays for Smyrindioloside are not well-characterized. As a coumarin-type natural product, its activity could be assessed using standard assays for antioxidant activity (e.g., DPPH, ABTS), anti-inflammatory activity (e.g., cytokine inhibition), or enzyme inhibition. However, specific assay protocols are not extensively reported.
|
| Cell Assay |
Cellular assays for Smyrindioloside are limited. The compound could be tested in various cell lines to assess its effects on cell viability, inflammation, or oxidative stress. However, specific cellular assay protocols are not extensively reported. The compound is primarily used as a chemical reference standard.
|
| Animal Protocol |
In vivo animal studies for Smyrindioloside are limited. The compound is primarily used as a research tool for biochemical experiments and drug synthesis research. Specific in vivo study protocols are not reported.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Smyrindioloside have not been characterized. The compound has a molecular weight of 424.40 and a molecular formula of C20H24O10. Detailed PK parameters such as half-life, bioavailability, and volume of distribution are not reported. The compound is typically stored at -20degC.
|
| Toxicity/Toxicokinetics |
Toxicological data for Smyrindioloside are limited. The compound is not intended for human therapeutic use and is supplied for research purposes only. The compound is derived from natural sources and is considered to have low toxicity. Standard safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
Psoralen compounds include psoralen glycosides. It has been reported that psoralen glycosides have been found in Angelica pubescens, Euphorbia pekinensis, and other organisms for which relevant data are available.
Smyrindioloside is a coumarin-type natural product from Streblus indicus and Smyrnopsis aucheri. It is used in biochemical experiments and drug synthesis research. The compound is not an FDA-approved drug and has no clinical indications. It is available in high purity (≥98%) and is typically stored at -20degC. |
| Molecular Formula |
C20H24O10
|
|---|---|
| Molecular Weight |
424.3986
|
| Exact Mass |
424.136
|
| CAS # |
87592-77-6
|
| PubChem CID |
10836072
|
| Appearance |
White to off-white solid
|
| Density |
1.6±0.1 g/cm3
|
| Boiling Point |
685.8±55.0 °C at 760 mmHg
|
| Flash Point |
243.3±25.0 °C
|
| Vapour Pressure |
0.0±2.2 mmHg at 25°C
|
| Index of Refraction |
1.670
|
| LogP |
-1.86
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
30
|
| Complexity |
681
|
| Defined Atom Stereocenter Count |
7
|
| SMILES |
O[C@H]1[C@@H](C(C)(C)O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC2C=C3OC(=O)C=CC3=CC1=2
|
| InChi Key |
KLPNFWKZLQAVTH-LDCXIIFCSA-N
|
| InChi Code |
InChI=1S/C20H24O10/c1-20(2,30-19-17(26)16(25)15(24)12(7-21)29-19)18-14(23)9-5-8-3-4-13(22)27-10(8)6-11(9)28-18/h3-6,12,14-19,21,23-26H,7H2,1-2H3/t12-,14-,15-,16+,17-,18+,19+/m1/s1
|
| Chemical Name |
(2S,3R)-3-hydroxy-2-[2-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl]-2,3-dihydrofuro[3,2-g]chromen-7-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~25 mg/mL (~58.91 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3563 mL | 11.7813 mL | 23.5627 mL | |
| 5 mM | 0.4713 mL | 2.3563 mL | 4.7125 mL | |
| 10 mM | 0.2356 mL | 1.1781 mL | 2.3563 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
